Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Diseases patents

      

This page is updated frequently with new Autoimmune Diseases-related patent applications.




 Monomers and oligonucleotides comprising cycloaddition adduct(s) patent thumbnailMonomers and oligonucleotides comprising cycloaddition adduct(s)
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

 Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring patent thumbnailMethods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of tigit, flg2 and/or il-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection).
The Brigham And Women's Hospital, Inc.


 Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases patent thumbnailHuman anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
Medimmune Limited


 Modulating gamma-c-cytokine activity patent thumbnailModulating gamma-c-cytokine activity
Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


 Crystalline forms of a bruton's tyrosine kinase inhibitor patent thumbnailCrystalline forms of a bruton's tyrosine kinase inhibitor
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


 Methods for treating or preventing neuroinflammation or autoimmune diseases patent thumbnailMethods for treating or preventing neuroinflammation or autoimmune diseases
Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.. .

 Human antibodies to human tnf-like ligand 1a (tl1a) patent thumbnailHuman antibodies to human tnf-like ligand 1a (tl1a)
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
Regeneron Pharmaceuticals, Inc.


 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases patent thumbnailApoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


 Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same patent thumbnailNovel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
The present invention relates to novel compounds having histone deacetylase 6 (hdac6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (hdac6) inhibitory activity, and are effective for the prevention or treatment of hdac6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders..
Chong Kun Dang Pharmaceutical Corp.


 Nucleic acid that inhibits expression of irf5 patent thumbnailNucleic acid that inhibits expression of irf5
The present invention provides a nucleic acid having activity to suppress expression of irf5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.. .
Kyowa Hakko Kirin Co., Ltd.


Fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof

The present invention provides a fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking baff/appril, and may significantly lower the serum igm concentration in normal balb/c mice as well as the serum igm and ige concentration in c57/b6 mice with asthma.
Shanghai Celgen Bio-pharmaceutical Co., Ltd.

Novel compounds

The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited

Compositions and methods for modulating the immune system

A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc

Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Marker sequences for diagnosing and stratifying sle patients

The present invention relates to methods for identifying markers for systemic lupus erythematosus (sle) and to the markers identified with the aid of this method, which can differentiate between sle and other autoimmune diseases on the one hand and between different sle subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in sle.
Protagen Ag

Sequencing-directed selection of tumor theranostics

The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins..
Affigen, Inc.

Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay

Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-mhc complexes are in many cases inadequate for a number of reasons.
The Johns Hopkins University

Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto

This disclosure relates to recombinant proteins comprising a gm-csf sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises n-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer..
Children's Healthcare Of Atlanta, Inc.

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis

The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular

Substituted amino triazoles useful as human chitinase inhibitors

Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.

Indole carboxamide compounds

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways

Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.

Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment

The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Incorporated

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons.. .

Medicament for treating peripheral neuropathies

The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkinson's disease, anemia, cytopenia those among the diagnostic criteria..

Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes..
The Children's Hospital Of Philadelphia

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals

2,2'-tandem dithiazole compound, preparation method therefor, and use thereof

The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2′-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2′-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type ii diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases..
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Compositions having means for targeting at least one antigen to dendritic cells

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
Universite Paris Descartes

Substituted bicyclic compounds

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Elisa for a naturally-occurring soluble truncated form of il-23 receptor

A naturally-occurring soluble truncated il-23rα protein (i.e., Δ9 il-23rα) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (elisa) and test kit for the serological detection of the soluble truncated form of il-23rα protein.
Medical Diagnostic Laboratories, Llc

Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd8+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd8+ treg cells with migratory character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd8+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd8+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd8+ treg cell populations of target tissue a, to identify emigrant cd8+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd8+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd8+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd8+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Method for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd4+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd4+ treg cells with migratory in character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd4+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd4+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd4+ treg cell populations of target tissue a, to identify emigrant cd4+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd4+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd4+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd4+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Anti-human il-21 antibodies

Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Zymogenetics, Inc.

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof

The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer..
Biocellchallenge

Pharmaceutical compositions containing beta-2 microglobulin and methods of treating autoimmune diseases

A pharmaceutical product containing β2-microglobulin or a functional variant thereof as an active ingredient in the form of liposomes is provided. The product can increase the concentration of β2-microglobulin in the blood, and can also restore a normal hc/β2-microglobulin molar ratio within membrane mhc-i complexes, or prevent a β2-microglobulin deficit from occurring in the mhc-i complexes, of patients suffering from autoimmune diseases.
Beta Innov

Use of glycan as biomarkers for autoimmune diseases

The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed..
Macau University Of Science And Technology

Stimulation via tlr4/md-2 to reverse type 1 diabetes

Disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati

Anti-bcma antibodies

This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Ma Inc.

Nkt cell ligands and methods of use

Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity

Mmf-derivatives of ethyleneglycols

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University

Autoimmunity and multiple sclerosis treatment

A method for alleviating a symptom of multiple sclerosis or other autoimmune or inflammatory disease includes a step of identifying a subject having multiple sclerosis or other autoimmune diseases. A fasting mimicking diet is administered to the subject for a first predetermined time period, the fasting mimicking diet providing less than 50% of the subject's normal caloric intake.
University Of Southern California

Surrogates of post-translationally modified proteins and uses thereof

The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
President And Fellows Of Harvard College

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Biogen Inc.

Combination therapy for the treatment of autoimmune diseases

The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.

Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases

A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..



Autoimmune Diseases topics:
  • Immune Diseases
  • Autoimmune Disease
  • Autoimmune Diseases
  • Immune Disease
  • Autoimmune
  • Rheumatoid Arthritis
  • Antibodies
  • Proliferative
  • Nucleotide
  • Antagonist
  • Infectious Diseases
  • Inflammatory Disease
  • Infectious Disease
  • Infectious
  • Multiple Sclerosis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4046

    file did exist - file did put2802

    3 - 1 - 51